Back to Search
JOHN SARKARIA, M.D.
M.D.
Pediatrics Physician
NPI: 1245250695Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
G063280(CA)
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
G063280(CA)
Research & Publications (20)
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
PMID 17363510·Mol Cancer Ther·2007
4-observational
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
PMID 19174557·Mol Cancer Ther·2009
7-preclinical
Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.
PMID 18931645·Otol Neurotol·2009
7-preclinical
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
PMID 19011762·J Neurooncol·2009
7-preclinical
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
PMID 18952979·Neuro Oncol·2009
7-preclinical
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
PMID 18955445·J Clin Oncol·2008
3-trial
p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
PMID 19074867·Cancer Res·2008
7-preclinical
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
PMID 18665158·Mol Ther·2008
7-preclinical
PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.
PMID 18559622·Clin Cancer Res·2008
7-preclinical
Mechanisms of chemoresistance to alkylating agents in malignant glioma.
PMID 18483356·Clin Cancer Res·2008
6-review
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
PMID 18445700·Neuro Oncol·2008
8-other
Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes.
PMID 19018242·J Neuropathol Exp Neurol·2008
7-preclinical
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
PMID 18286491·Head Neck·2008
7-preclinical
Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
PMID 18056196·Clin Cancer Res·2007
7-preclinical
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
PMID 17886562·J Neurosurg·2007
7-preclinical
Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer.
PMID 17762343·J Thorac Oncol·2007
3-trial
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
PMID 16985072·Mol Cancer Ther·2006
8-other
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
PMID 16609043·Clin Cancer Res·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 14642 NEWPORT AVE, SUITE 450
TUSTIN, CA 92780 - Phone
- (714) 669-4449
Quick Facts
- NPI
- 1245250695
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile